Fangsheng Pharmaceutical: Adenosine Cobalamin Capsules Obtain Drug Registration Certificate

Fangsheng Pharmaceutical announced that the company has received the Drug Registration Certificate for Adenosine Cobalamin Capsules approved and issued by the National Medical Products Administration. The drug is a Class 3 chemical drug with a specification of 0.5 mg. The drug approval number is valid until October 12, 2031, and both the marketing authorization holder and the manufacturing enterprise are the company. Adenosine Cobalamin Capsules are indicated for megaloblastic anemia, polyneuritis, and other conditions, and can also be used as adjuvant therapy for leukopenia. As of the announcement date, the cumulative investment in this drug project reached 3.2911 million yuan. This approval is conducive to enriching the company's product portfolio and is not expected to have a significant impact on the company's performance in the short term.